Compare PAYP & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYP | TGTX |
|---|---|---|
| Founded | 2018 | 1993 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 8.5B |
| IPO Year | 2026 | 2008 |
| Metric | PAYP | TGTX |
|---|---|---|
| Price | $14.62 | $52.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $25.54 | ★ $49.80 |
| AVG Volume (30 Days) | 1.5M | ★ 2.8M |
| Earning Date | 08-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | N/A | ★ 0.12 |
| Revenue | N/A | ★ $2,785,000.00 |
| Revenue This Year | N/A | $49.08 |
| Revenue Next Year | $20.92 | $26.69 |
| P/E Ratio | ★ N/A | $444.67 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.07 | $25.37 |
| 52 Week High | $24.89 | $57.38 |
| Indicator | PAYP | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.82 | 65.01 |
| Support Level | $12.07 | $28.57 |
| Resistance Level | $23.11 | $57.38 |
| Average True Range (ATR) | 0.99 | 2.42 |
| MACD | 0.30 | -0.13 |
| Stochastic Oscillator | 79.31 | 49.59 |
PayPay is a fintech company jointly owned by Softbank and LY. It was founded in 2018, following the success of Alipay and WeChat Pay in China, and was the pioneering code payment app in Japan. Over the past seven years, it has amassed more than 70 million users and is the market leader in code payments.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.